

## Global Radiopharmaceuticals Market – Products and Applications

*“The report reviews, analyzes and projects the global market for Radiopharmaceuticals for the period 2016-2025. The market for Radiopharmaceuticals product types analyzed in this study includes SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Others comprising Brachytherapy, Auger electron, Coster-Kronig electron etc. The study also explores the market for Radiopharmaceutical applications consisting Oncology, Cardiology, Neurology, Endocrinology, and Others comprising Nephrology, Immunology and Orthopedics etc.”*

Published: October 2019

Report Code: HC025

Pages: 380

Charts: 235

Price: \$4500 Single User License, \$7200 Enterprise License

### Report Synopsis

Rising prevalence of cancer and cardiovascular diseases are the main factors driving the Radiopharmaceuticals market. Technological advancement, elevated healthcare expenditure, prevalence of chronic ailments, increasing geriatric population, rising awareness of Radiopharmaceuticals applications in disease treatment, poor dietary habits, unhealthy lifestyle and increased awareness about the benefits of targeted alpha therapy are some of the other key factors fueling the Radiopharmaceuticals market.

SPECT Radioisotopes constitute the single largest product type in global radiopharmaceuticals market, demand for which is expected to reach US\$2.7 billion in 2019 while Beta Emitters is projected the fastest growing Radiopharmaceuticals product type globally during the analysis period 2018-2025 with a CAGR of 13.7%. Overall market for Radiopharmaceuticals in 2019 is expected to touch US\$6.1 billion.

### Research Findings & Coverage

- Global research report on Radiopharmaceuticals market, analyzes the market with respect to product types and applications
- Radiopharmaceuticals' market size is estimated in this report by product types and applications across all major regions/countries
- Recurrent Prostate Cancer Detection by a New PET Radiopharmaceutical
- Plate Heat Exchanger Applications Growing
- New Therapeutic Radiotracers for Malignant Neuroendocrine Tumors
- Copper – A Promising Novel Theranostic Radiopharmaceutical
- Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
- Major companies profiled – 41
- The industry guide includes the contact details for 100 companies

### Product Outline

The market for key product types of Radiopharmaceuticals studied in this report comprises the following:

- SPECT Radioisotopes
- PET Radioisotopes
- Beta Emitters
- Alpha Emitters
- Other

The report analyzes the market for the following applications of Radiopharmaceuticals:

- Oncology
- Cardiology
- Neurology
- Endocrinology
- Other


### Analysis Period, Units and Growth Rates

- The report reviews, analyzes and projects the global Radiopharmaceuticals market for the period 2016-2025 in terms of market value in US\$ and the compound annual growth rates (CAGRs) projected from 2018 through 2025.

### Geographic Coverage

- **North America** (The United States and Mexico)
- **Europe** (Germany, United Kingdom, France, Italy, Sweden and Rest of Europe)
- **Asia-Pacific** (Japan, China, India, Australia, South Korea and Rest of Asia-Pacific)
- **Rest of World** (Mexico, Brazil and Other ROW Countries)

Global Radiopharmaceuticals Market by Product Type 2018-2025



## SAMPLE COMPANY PROFILE

### ALPHA TAU MEDICAL LTD. (ISRAEL)

School of Physics, Tel Aviv University, P.O. Box 39040  
Tel Aviv 6997801, Israel  
Phone: +972-3-741-3117  
Fax: +972-3-741-3117  
Email: info@alphatau.com  
Website: www.alphatau.com

#### Business Profile

Israel-based MedTech company, Alpha Tau Medical Ltd. engages in research, development and marketing of Alpha DaRT (Diffusing Alpha emitters Radiation Therapy) to treat solid cancers. In 2003, Alpha Tau developed a technology called Alpha DaRT technology at Tel Aviv University. Alpha tau has performed numerous clinical trials to elucidate the effect of Alpha DaRT technology in treating solid cancers. The company is headquartered at Israel and has an office at the United States. Alpha Tau aims at evaluating the therapeutic potential of radium in treating cancer through research and alliances.

#### The Alpha DaRT Technology

Alpha DaRT technology facilitates solid cancer treatment by delivering Alpha DaRT seed that consists of Radium-224 atoms beneath its surface. The seed is injected into the tumor mass so that the short alpha emitting atoms are liberated into the mass without causing any damage to the surrounding healthy tissue. By diffusion and convection, the atoms move within several millimeters of distance and delivers high radiation dosages inside the tumor mass.

#### Preclinical Studies

Alpha tau is conducting in vitro and in vivo preclinical trials in eight mouse tumor models and ten human derived tumors to elucidate the therapeutic effect of Diffusing Alpha-Emitters Radioactive Therapy (DaRT). Furthermore, an experiment was performed in a goat to evaluate the effect of radioactive wires in normal tissues and blood vessels by injecting Ra-224 implanted stainless steel wires directly into the tumor.

#### Clinical Studies

Alpha Tau strongly believes that the therapeutic potential of Alpha DaRT in treating cancer can be evaluated through research collaborations and thereby save millions of patients suffering with cancer. Hence, the company has formed clinical collaborations with major cancer institutes in North America, Europe, and Asia. At present, Alpha Tau conducts clinical trials in Squamous Cell Carcinoma (SCC) of the Skin and Head and Neck, and Skin and Oral Cavity Cancer (CMN) and the upcoming projects includes Vulva cancer (Europe), prostate cancer (North American and Europe), breast cancer (Europe), pancreatic cancer (North America), skin cancer, SCC, CMN (North America and Europe), and head and neck cancer (North America and Europe).


.....more

## SAMPLE TABLE/CHART

Glance at 2019 Global Radiopharmaceuticals Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific and Rest of World



North American Radiopharmaceuticals Market Analysis (2016-2025) by Product Type – SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other in USD Million



## KEY PLAYERS PROFILED

- Advanced Accelerator Applications SA
- Alpha Tau Medical Ltd.
- Bayer AG
- Blue Earth Diagnostics Limited
- Bracco Diagnostics, Inc.
- Cardinal Health, Inc.
- Clarity Pharmaceuticals
- Curium Pharma
- Eckert & Ziegler Group
- Eczacibasi-Monrol
- GE Healthcare
- Ion Beam Applications SA (IBA)
- Jubilant DraxImage, Inc. dba Jubilant Radiopharma
- Lantheus Medical Imaging, Inc.
- Life Molecular Imaging GmbH
- NTP Radioisotopes SOC Ltd.
- Orano Med
- Siemens Healthineers
- Telix Pharmaceuticals Limited

.....more

## TABLE OF CONTENTS

### PART A: GLOBAL MARKET PERSPECTIVE ..... 1

#### 1. INTRODUCTION ..... 1

1.1 Product Outline.....	4
1.1.1 Radiopharmaceuticals Introduction.....	4
1.1.2 What are Radiopharmaceuticals?.....	4
1.1.2.1 Historical Timeline – Radiopharmaceuticals ..	6
1.1.2.2 Radiopharmaceutical Nomenclature .....	8
1.1.2.3 Radiation Measurement Units .....	8
1.1.2.4 Route of Administration .....	8
1.1.2.5 Prerequisites for Nuclear Imaging.....	8
1.1.2.6 Possible Complications of Radioisotopes.....	8
1.1.2.7 Misadministration of Radiopharmaceuticals ..	9
1.1.3 Radiopharmaceuticals Production .....	9
1.1.3.1 Cyclotron .....	9
1.1.3.2 Nuclear Reactor .....	11
1.1.3.3 Radionuclide Generator.....	11
1.1.4 Benefits and risks of Nuclear Imaging.....	12
1.1.4.1 Benefits.....	12
1.1.4.2 Risks.....	12
1.1.5 Radiopharmaceuticals Segmentation Based on	
Usage.....	13
1.1.5.1 Diagnostic Radiopharmaceuticals .....	15
1.1.5.2 Therapeutic Radiopharmaceuticals.....	15
1.1.6 Some Important Radiotracers.....	16
1.1.6.1 Technetium-99m .....	16
1.1.6.2 TL-201 .....	16
1.1.6.3 Ga-67 .....	16
1.1.6.4 I-123.....	16
1.1.6.5 F-18 .....	16
1.1.6.6 Ra-223.....	17
1.1.6.7 I-131.....	17
1.1.6.8 I-125.....	17
1.1.6.9 Ir-192 .....	17
1.1.7 Types of Radiopharmaceuticals .....	18
1.1.7.1 SPECT Radioisotopes.....	21
1.1.7.2 PET Radioisotopes.....	22
1.1.7.3 Beta Emitters .....	22
1.1.7.4 Alpha Emitters .....	22
1.1.7.5 Brachytherapy.....	23
1.1.7.5.1 Temporary Brachytherapy .....	23
1.1.7.5.2 Permanent Brachytherapy .....	23
1.1.7.6 Auger Electron .....	23
1.1.7.7 Coster-Kronig Electron .....	23
1.1.8 Applications of Radiopharmaceuticals .....	24
1.1.8.1 Oncology.....	24
1.1.8.2 Cardiology.....	26
1.1.8.3 Neurology .....	28
1.1.8.4 Endocrinology.....	30
1.1.8.5 Other Applications .....	32
1.1.9 Radiopharmaceuticals Approval Procedure .....	34
1.1.9.1 The United States.....	34
1.1.9.2 Europe .....	34

#### 2. KEY MARKET TRENDS ..... 35

2.1 Recurrent Prostate Cancer Detection by a New	
PET Radiopharmaceutical .....	35
2.2 Radiopharmaceuticals Enable Easy Monitorization	
of Rheumatoid Arthritis .....	35
2.3 68Ga-FAPI Radiotracer – A Novel Tracer Capable	
of Detecting Approximately Thirty Cancer Types.....	36
2.4 Novel SV2A PET Tracer for Neurodegenerative	
Disorder .....	36
2.5 New Therapeutic Radiotracers for Malignant	
Neuroendocrine Tumors.....	37
2.6 Copper – A Promising Novel Theranostic	
Radiopharmaceutical .....	37

2.7 A Novel PET Radioisotope Tool to Diagnose Brain	
Disorders .....	37
2.8 [18F]RO-948 - Tau PET Radiopharmaceuticals for	
Alzheimer's Disease .....	38
2.9 Particle Accelerator Capable of Producing	
Technetium-99m Radioisotope .....	38
2.10 Treatment Response Prediction of Bone-Dominant	
Metastatic Breast Cancer by PET Radiotracer .....	38

#### 3. KEY GLOBAL PLAYERS..... 39

Advanced Accelerator Applications SA (France).....	39
Alpha Tau Medical Ltd. (Israel).....	40
Bayer AG (Germany) .....	41
Blue Earth Diagnostics Limited (United Kingdom) .....	42
Bracco Diagnostics, Inc. (United States) .....	43
Cardinal Health, Inc. (United States) .....	44
Clarity Pharmaceuticals (Australia) .....	45
Curium Pharma (France) .....	47
Eckert & Ziegler Group (Germany) .....	50
Eczacıbasi-Monrol (Turkey) .....	52
GE Healthcare (United States).....	54
Ion Beam Applications SA (IBA) (Belgium).....	55
Jubilant DraxImage, Inc. dba Jubilant Radiopharma	
(Canada) .....	57
Lantheus Medical Imaging, Inc. (United States) .....	59
Life Molecular Imaging GmbH (Germany).....	61
NTP Radioisotopes SOC Ltd. (South Africa) .....	62
Orano Med (France).....	63
Siemens Healthineers (Germany).....	64
Telix Pharmaceuticals Limited (Australia).....	65

#### 4. KEY BUSINESS AND PRODUCT TRENDS ..... 66

Clarity Pharmaceuticals Files ODD Request for 64Cu-	
SARTATE™ .....	66
Theranostic IND Application for 64Cu-SARTATE™ and	
67Cu-SARTATE™ Filed by Clarity Pharmaceuticals.....	66
IBA Installs Cyclone® 70 Cyclotron System in Cape Town,	
South Africa .....	66
Eckert & Ziegler and Alpha Tau Form Thorium-228 Supply	
Pact .....	67
Varian Installs Cyclotron for ProBeam® Proton Therapy	
System at Sylvester Comprehensive Cancer Center .....	67
Blue Earth Diagnostics Acquired by Bracco Imaging.....	67
TCL Eckert & Ziegler BEBIG Healthcare to Produce and	
Market Tumor Irritation Devices in China .....	67
IBA Installs Cyclone® 70 System in Daejeon, South Korea	
68 .....	68
New Radiopharmaceutical Production Unit Established by	
EZAG in China.....	68
NorthStar Enhances the Production Capacity of Non-	
Uranium Based Radioisotopes .....	68
Swedish Karolinska University Hospital Employs Varian's	
Bravos™ Afterloader System for HDR Brachytherapy	
Treatment .....	68
New Molybdenum-99 Processing Facility Established by	
NorthStar in Beloit, Wisconsin .....	69
Varian Installs Cyclotron for ProBeam® Proton Therapy	
System at King Chulalongkorn Memorial Hospital in	
Bangkok .....	69
Doctors Hospital in Mexico Installed with New Synthera®	
Platform .....	69
Progenics' AI Research Program to Explore Novel Machine	
Learning Algorithms in Medical Imaging .....	70
DuChemBio to Produce and Market Life Molecular	
Imaging's NeuraCeq™ in Philippines .....	70
ANSTO's National Research Cyclotron Facility to	
Manufacture F-18 Radiotracers .....	70
US FDA Issues 510(k) Clearance for DOSIsof's Planet Onco	
Dose Software.....	70
First Clinical Installation of United Imaging's uMI 550	
Digital PET/CT System in the United States .....	71
Vivos Receives License for Administering IsoPet® for	
Animal Therapy .....	71
Launch of IMWG's First Set of New Recommendations for	
Multiple Myeloma Imaging Techniques .....	71
Cancer Treatment Services International Acquired by	
Varian .....	71

Launch of Jubilant Radiopharma .....	71
CE Marking for Jubilant DraxImage's RUBY Rubidium	
Elution System and Proprietary RUBY Consumable	
Accessories.....	72
New Production Method for Medical Imaging	
Radioisotopes Unveiled by BGN Technologies.....	72
Integrated Use of NeuraCeq™ and PI-2620 Radiotracers	
for Brain PET Imaging in Thailand .....	72
Fujifilm Toyama Chemical Takeover Progenics' Automated	
Bone Scan Index Product in Japan .....	72
Varian Installs Cyclotron for ProBeam® Proton Therapy	
System at Biopolis .....	73
New Multi-Room Proton Clinical Research Center of	
Shandong Cancer Hospital Equipped with Varian	
ProBeam® Proton Therapy System.....	73
CyberHeart Acquired by Varian .....	73
Cyclone® KIUBE Installation Increases ICNAS'	
Radiopharmaceutical Production .....	73
ROTOP to Develop and Commercialize Progenics' 1404	
Prostate Cancer Imaging Agent in Europe .....	73
Cyclotron for Varian ProBeam® Compact Proton Therapy	
System Installed at Hefei Ion Medical Center .....	74
IRAB to Produce Life Molecular Imaging's NeuraCeq™ and	
PI-2620 in Barcelona.....	74
Orano Med Invests 15 Million Euros to Enhance the	
Production of Cancer Therapeutic Solutions.....	74
Cyclone® KIUBE Cyclotron Equipped at Costa Rica	
University .....	75
Coqui's Medical Isotope Production Facility Built in Oak	
Ridge, Tennessee.....	75
NorthStar Acquires IBA's Eight Rhodotron® TT300 HE	
Electron Beam Accelerators.....	75
INCART to Produce FDG.....	75
RadioMedix to Develop Vect-Horus Theranostic Agent for	
Glioblastoma Multiforme .....	75
EZAG Completes Merger of EZB.....	76
First Commercial Production of Blue Earth Diagnostics'	
Axumin® in Italy.....	76
Health Canada Approves AAA's Lutathera™ for GEP-NETs	
Treatment .....	76
GE Healthcare Installs PETtrace 880 Cyclotron at KIRAMS.....	76
AZEDRA® Production Facility in Somerset, New Jersey	
Acquired by Progenics .....	77
Bacon Lab in Argentina Starts Clinical Trials with 18F-	
PSMA-1007 .....	77
HUS Imaging to Kick-off FDG Production .....	77
Curium to Develop and Commercialize Progenics' Pyl™	
Prostate Cancer Imaging Agent in Europe .....	77
RadioMedix' 64Cu-Dotatate Receives Fast Track	
Designation from US FDA .....	77
Endocyte Acquired by Novartis.....	78
First Commercial Production of Blue Earth Diagnostics'	
Axumin® in France.....	78
US FDA Accepted for sNDA Review to Employ Axumin® for	
Glioma Assessment .....	78
USPTO Extends Patent Term for Lymphoseek® .....	78
AAA to Develop and Commercialize Fujifilm Toyama	
Chemical's FF-10158 for Oncology Indications .....	78
CIMEQ to Produce FDG in Cuba.....	79
Advanced Nuclear Medicine Ingredients SA Acquired by	
Telix Pharmaceuticals.....	79
US FDA Grants ODD to Employ AlphaMedix™ for	
Neuroendocrine Tumor Treatment .....	79
Novartis to Broaden RLT platform by Acquiring Endocyte .	
79 .....	79
GMP Production Deal Signed by Telix and RTM for Kidney	
Imaging.....	80
Seibersdorf Laboratories to Produce Telix' Glioblastoma	
Therapeutics.....	80
Telix Pharmaceuticals Joined Forces with Cardinal Health	
for the Supply of 68Ga-PSMA Kit in US .....	80
Fujifilm Toyama Chemical to Develop Novel Diagnostic and	
Therapeutic Drugs .....	80
NorthStar Awarded as the First Molybdenum-99 Producer	
in US .....	81
Ruffani Quality Solutions is the New Local Partner of Trasis	
in Germany and Austria.....	81

Trasis Produces PSMA Based Radiotracers on AllinOne Family Synthesizer.....81	Telix to Develop and Commercialize ANMI's 68Ga-PSMA-11 Kit in US.....91	6.2.1.3 Beta Emitters ..... 133
Trasis' FDG Dual Method Receives Market Authorization for Belgium and the Netherlands .....81	RadioMedix to Distribute ITG's n.c.a. Lutetium-177 in North America .....91	6.2.1.4 Alpha Emitters ..... 135
XingImaging Sites in China to Produce Life Molecular Imaging's PI2620 .....81	Triad's US Radiopharmacy Business Acquired by Jubilant Pharma .....91	6.2.1.5 Other Radiopharmaceuticals ..... 137
Atlab Pharma Purchased by Telix Pharmaceuticals .....82	NNSA and NTP Completes Molybdenum-99 Conversion Project .....91	6.3 North American Radiopharmaceuticals Market Overview by Application ..... 139
Life Molecular Imaging is the New Name of Piramal Imaging .....82	Cardinal Health to Distribute IRE-ELI's Galli Eo® 68Ge/68Ga Generator in North America .....92	6.3.1 Radiopharmaceuticals Application Market Overview by NA Region ..... 141
Novel Phospholipid Drug Conjugate Co-developed by Colletcar and Orano Med .....82	Varian to Distribute Bionix® Brachytherapy Applicators in North America .....92	6.3.1.1 Oncology ..... 141
Curium to Develop and Commercialize RadioMedix' 64Cu-Dotatate .....82	Telix Pharmaceuticals Completed Master Services Agreement with Cyclotek .....92	6.3.1.2 Cardiology ..... 143
US FDA Approves NorthStar's Beloit Manufacturing Facility for RadioGenix™ System Production .....83	Sayre Therapeutics to Develop and Commercialize Navidea's Tc 99m Tilmanocept in India .....93	6.3.1.3 Neurology ..... 145
US FDA Issues 510(k) Regulatory Clearance for IsoRay's GammaTile™ Therapy .....83	SpePharm AG Launches Navidea's LYMPHOSEEK® Tc 99m Tilmanocept .....93	6.3.1.4 Endocrinology ..... 147
US FDA Approves NDA for Progenics' AZEDRA® (Iobenguane I 131) 555 MBq/mL Injection .....83	EC Grants Marketing Authorisation for Blue Earth Diagnostics' Axumin™ .....93	6.3.1.5 Other Applications ..... 149
RadioMedix to Produce and Supply Next Generation ITG Ge-68 / Ga-68 Generators .....83	ARTMS Products and Alliance Medical Join Forces to Demonstrate a Viable Alternative .....93	6.4 Major Market Players ..... 151
Installation of the First New Generation IBA Cyclone® KIUBE Cyclotron in Russia .....84	Alliance Medical to Takeover Eckert & Ziegler's Cyclotron Division .....94	Actinium Pharmaceuticals, Inc. (United States) ..... 151
Piramal Imaging Acquired by Alliance Medical .....84	Cyclone® 18 Placed into Vault at INCART .....94	Bracco Diagnostics, Inc. (United States) ..... 152
IASON to Produce and Distribute Blue Earth Diagnostics' Axumin® in Poland .....84	Implementation of 18F-PSMA-1007 on IBA Synthera® Platform .....94	Cardinal Health, Inc. (United States) ..... 153
IBA Cyclone® KIUBE 300 has the Highest Production Capacity Ever Reached by a PET Cyclotron .....85	Unveiling of IBA's Novel Fixed IFP™ Cassette at an Expo in Germany .....94	Coqui Pharma (United States) ..... 154
IBA Cyclone® 18 Placed in Vault at Muni Seva Ashram in India .....85	Trasis Joined Forces with Herlev Hospital to Produce 18F NaF and 18F FDOPA on Daily Basis .....94	Fusion Pharmaceuticals, Inc. (Canada) ..... 155
Installation of IBA Cyclone® 70 System at AZI in United States .....85	ANSTO Researchers Developed Novel PET Radiotracer Production Process .....95	GE Healthcare (United States) ..... 156
AtomExpo Award Received by NTP Radioisotopes .....85	Curium, Merger of IBA Molecular and Mallinckrodt Nuclear Medicine LLC .....95	Isologic Innovative Radiopharmaceuticals Ltd. (Canada) ..... 157
Blue Earth Diagnostics Acquires Selective Global Licensing Rights of Scintomics' rhPSMA-targeted Agents for Cancer Imaging .....85	Cardinal Health Purchased Licensing Rights of Navidea's Lymphoseek® in North America .....95	Isoray Medical, Inc. (United States) ..... 159
SWAN Isotopen AG to Produce and Distribute Piramal Imaging's NeuraCeq™ in Switzerland .....86	University of Missouri Research Reactor to Supply Lutetium 177 to Advanced Accelerator Applications .....95	Jubilant DraxImage, Inc. dba Jubilant Radiopharma (Canada) ..... 160
Curium Re-Introduces Xenon Xe 133 Gas .....86	Health Canada Issues Notice of Compliance to ISOLOGIC Innovative Radiopharmaceuticals for NeuraCeq™ .....96	Lantheus Medical Imaging, Inc. (United States) ..... 162
Cyclopharma's Production and Commercial Operations in France Acquired by Curium .....86	All Medrad Intego PET Infusion System Source Administration Sets Recalled by Bayer .....96	Navidea Biopharmaceuticals, Inc. (United States) ..... 164
Meilleur to Develop and Commercialize Navidea's NAV4694 Imaging Agent .....86	<b>5. GLOBAL MARKET OVERVIEW ..... 97</b>	NorthStar® Medical Radioisotopes LLC (United States) ..... 165
Permanent Shut Down of Canada's National Research Universal .....86	<b>5.1 Global Radiopharmaceuticals Market Overview by Product Type ..... 98</b>	Pharmalucence, Inc. (United States) ..... 167
Cyclone® 18 at JFE Site Set for Radioisotope Production .....87	<b>5.1.1 Radiopharmaceuticals Product Type Market Overview by Global Region ..... 100</b>	Progenics Pharmaceuticals, Inc. (United States) ..... 168
Cyclone® KIUBE to be Installed at GMS Taichung Production Facility in Taiwan .....87	<b>5.1.1.1 SPECT Radioisotopes ..... 100</b>	Radiomedix, Inc. (United States) ..... 169
Positron Pharma to Produce and Distribute Piramal Imaging's NeuraCeq™ Imaging Agent .....87	<b>5.1.1.2 PET Radioisotopes ..... 102</b>	Vivos, Inc. (United States) ..... 170
NorthStar's RadioGenix™ System Receives US FDA Approval .....87	<b>5.1.1.3 Beta Emitters ..... 104</b>	Zevacor Molecular (United States) ..... 171
Advanced Accelerator Applications to Develop and Market F-18-labeled CTT1057 .....87	<b>5.1.1.4 Alpha Emitters ..... 106</b>	
Successful Rigging of Cyclone® 18/9 at CNUH in South Korea .....88	<b>5.1.1.5 Other Radiopharmaceuticals ..... 108</b>	
Isologic to Distribute IRE-ELI's Galli Eo® 68Ge / 68Ga Generator in Canada .....88	<b>5.2 Global Radiopharmaceuticals Market Overview by Application ..... 110</b>	
World's First Prostate Cancer Surgery Using Blu Build Cesium-131 Brachytherapy System by MUSC's Hollings Cancer Center .....88	<b>5.2.1 Radiopharmaceuticals Application Market Overview by Global Region ..... 112</b>	
DaTscan™, the First Imaging Agent for Parkinsonian Syndrome Diagnosis Approved by Health Canada .....88	<b>5.2.1.1 Oncology ..... 112</b>	
Advanced Medical Isotope Corporation Renamed as Vivos Inc. .....88	<b>5.2.1.2 Cardiology ..... 114</b>	
US FDA Approves AAA's LUTATHERA® to Treat Somatostatin Receptor Positive GEP-NETS .....89	<b>5.2.1.3 Neurology ..... 116</b>	
Curium, the First and Only Producer in North America Offering 100% LEU Tc 99m Generators .....89	<b>5.2.1.4 Endocrinology ..... 118</b>	
Successful Rigging of Cyclone® Cyclotrons on Different Continents .....89	<b>5.2.1.5 Other Applications ..... 120</b>	
US FDA Approves New Pulmonary Indications for Jubilant DraxImage's DRAXIMAGE® DTPA Kit .....89	<b>PART B: REGIONAL MARKET PERSPECTIVE ..122</b>	
Memorial Sloan Kettering Cancer Center Employs Telix' 89Zr-girentuximab .....89	<b>REGIONAL MARKET OVERVIEW ..... 124</b>	
Patent Application on University of Melbourne's PSMA Prostate Cancer Targeting Agent In-Licensed by Clarity .....90	<b>6. NORTH AMERICA ..... 124</b>	
Cyclone® 18 Rigged at CIMEQ in Cuba .....90	<b>6.1 North American Radiopharmaceuticals Market Overview by Geographic Region ..... 125</b>	
US FDA Approves for the Extension of the In-Use Shelf Life of Jubilant DraxImage's DRAXIMAGE® MAA .....90	<b>6.2 North American Radiopharmaceuticals Market Overview by Product Type ..... 127</b>	
	<b>6.2.1 Radiopharmaceuticals Product Type Market Overview by NA Region ..... 129</b>	
	<b>6.2.1.1 SPECT Radioisotopes ..... 129</b>	
	<b>6.2.1.2 PET Radioisotopes ..... 131</b>	
	<b>6.2.1.3 Beta Emitters ..... 133</b>	
	<b>6.2.1.4 Alpha Emitters ..... 135</b>	
	<b>6.2.1.5 Other Radiopharmaceuticals ..... 137</b>	
	<b>6.3 North American Radiopharmaceuticals Market Overview by Application ..... 139</b>	
	<b>6.3.1 Radiopharmaceuticals Application Market Overview by NA Region ..... 141</b>	
	<b>6.3.1.1 Oncology ..... 141</b>	
	<b>6.3.1.2 Cardiology ..... 143</b>	
	<b>6.3.1.3 Neurology ..... 145</b>	
	<b>6.3.1.4 Endocrinology ..... 147</b>	
	<b>6.3.1.5 Other Applications ..... 149</b>	
	<b>6.4 Major Market Players ..... 151</b>	
	Actinium Pharmaceuticals, Inc. (United States) ..... 151	
	Bracco Diagnostics, Inc. (United States) ..... 152	
	Cardinal Health, Inc. (United States) ..... 153	
	Coqui Pharma (United States) ..... 154	
	Fusion Pharmaceuticals, Inc. (Canada) ..... 155	
	GE Healthcare (United States) ..... 156	
	Isologic Innovative Radiopharmaceuticals Ltd. (Canada) ..... 157	
	Isoray Medical, Inc. (United States) ..... 159	
	Jubilant DraxImage, Inc. dba Jubilant Radiopharma (Canada) ..... 160	
	Lantheus Medical Imaging, Inc. (United States) ..... 162	
	Navidea Biopharmaceuticals, Inc. (United States) ..... 164	
	NorthStar® Medical Radioisotopes LLC (United States) ..... 165	
	Pharmalucence, Inc. (United States) ..... 167	
	Progenics Pharmaceuticals, Inc. (United States) ..... 168	
	Radiomedix, Inc. (United States) ..... 169	
	Vivos, Inc. (United States) ..... 170	
	Zevacor Molecular (United States) ..... 171	
	<b>6.5 Country-wise Analysis of North American Radiopharmaceuticals Market ..... 172</b>	
	<b>6.5.1 The United States ..... 172</b>	
	<b>6.5.1.1 United States Radiopharmaceuticals Market Overview by Product Type ..... 173</b>	
	<b>6.5.1.2 United States Radiopharmaceuticals Market Overview by Application ..... 175</b>	
	<b>6.5.2 Canada ..... 177</b>	
	<b>6.5.2.1 Canadian Radiopharmaceuticals Market Overview by Product Type ..... 178</b>	
	<b>6.5.2.2 Canadian Radiopharmaceuticals Market Overview by Application ..... 180</b>	
	<b>7. EUROPE ..... 182</b>	
	<b>7.1 European Radiopharmaceuticals Market Overview by Geographic Region ..... 183</b>	
	<b>7.2 European Radiopharmaceuticals Market Overview by Product Type ..... 185</b>	
	<b>7.2.1 Radiopharmaceuticals Product Type Market Overview by European Region ..... 187</b>	
	<b>7.2.1.1 SPECT Radioisotopes ..... 187</b>	
	<b>7.2.1.2 PET Radioisotopes ..... 189</b>	
	<b>7.2.1.3 Beta Emitters ..... 191</b>	
	<b>7.2.1.4 Alpha Emitters ..... 193</b>	
	<b>7.2.1.5 Other Radiopharmaceuticals ..... 195</b>	
	<b>7.3 European Radiopharmaceuticals Market Overview by Application ..... 197</b>	
	<b>7.3.1 Radiopharmaceuticals Application Market Overview by European Region ..... 199</b>	
	<b>7.3.1.1 Oncology ..... 199</b>	
	<b>7.3.1.2 Cardiology ..... 201</b>	
	<b>7.3.1.3 Neurology ..... 203</b>	
	<b>7.3.1.4 Endocrinology ..... 205</b>	
	<b>7.3.1.5 Other Applications ..... 207</b>	
	<b>7.4 Major Market Players ..... 209</b>	
	Advanced Accelerator Applications SA (France) ..... 209	
	Alliance Medical Limited (The United Kingdom) ..... 210	
	Bayer AG (Germany) ..... 211	
	Blue Earth Diagnostics Limited (The United Kingdom) ..... 212	
	Curium Pharma (France) ..... 213	
	Eckert & Ziegler Group (Germany) ..... 217	
	Ion Beam Applications SA (IBA) (Belgium) ..... 219	

IRE - IRE ELIT (Belgium).....	221	8.3 Asia-Pacific Radiopharmaceuticals Market		9. REST OF WORLD.....	328
Life Molecular Imaging GmbH (Germany) .....	222	Overview by Application.....	276	9.1 Rest of World Radiopharmaceuticals Market	
Medi-Radiopharma Co., Ltd. (Hungary).....	223	8.3.1 Radiopharmaceuticals Application Market		Overview by Geographic Region.....	329
National Centre for Nuclear Research Radioisotope Centre		Overview by Asia-Pacific Region.....	278	9.2 Rest of World Radiopharmaceuticals Market	
POLATOM (Poland).....	225	8.3.1.1 Oncology.....	278	Overview by Product Type.....	331
Orano Med (France).....	227	8.3.1.2 Cardiology.....	280	9.2.1 Radiopharmaceuticals Product Type Market	
Siemens Healthineers (Germany).....	228	8.3.1.3 Neurology.....	282	Overview by Rest of World Region.....	333
Trasis (Belgium).....	229	8.3.1.4 Endocrinology.....	284	9.2.1.1 SPECT Radioisotopes.....	333
7.5 Country-wise Analysis of European		8.3.1.5 Other Applications.....	286	9.2.1.2 PET Radioisotopes.....	335
Radiopharmaceuticals Market.....	231	8.4 Major Market Players.....	288	9.2.1.3 Beta Emitters.....	337
<b>7.5.1 Germany.....</b>	<b>231</b>	Australian Nuclear Association and Technology		9.2.1.4 Alpha Emitters.....	339
7.5.1.1 German Radiopharmaceuticals Market		Organization (Australia).....	288	9.2.1.5 Other Radiopharmaceuticals.....	341
Overview by Product Type.....	232	Board of Radiation & Isotope Technology (BRIT) (India)	290	9.3 Rest of World Radiopharmaceuticals Market	
7.5.1.2 German Radiopharmaceuticals Market		China Isotope & Radiation Corporation (CIRC) (China).....	292	Overview by Application.....	343
Overview by Application.....	234	Clarity Pharmaceuticals (Australia).....	293	9.3.1 Radiopharmaceuticals Application Market	
<b>7.5.2 The United Kingdom.....</b>	<b>236</b>	FUJIFILM Toyama Chemical Co., Ltd. (Japan).....	295	Overview by Rest of World Region.....	345
7.5.2.1 United Kingdom Radiopharmaceuticals		Nihon Medi-Physics Co., Ltd. (Japan).....	296	9.3.1.1 Oncology.....	345
Market Overview by Product Type.....	237	Telix Pharmaceuticals Limited (Australia).....	297	9.3.1.2 Cardiology.....	347
7.5.2.2 United Kingdom Radiopharmaceuticals		8.5 Country-wise Analysis of Asia-Pacific		9.3.1.3 Neurology.....	349
Market Overview by Application.....	239	Radiopharmaceuticals Market.....	298	9.3.1.4 Endocrinology.....	351
<b>7.5.3 France.....</b>	<b>241</b>	<b>8.5.1 Japan.....</b>	<b>298</b>	9.3.1.5 Other Applications.....	353
7.5.3.1 French Radiopharmaceuticals Market		8.5.1.1 Japanese Radiopharmaceuticals Market		9.4 Major Market Players.....	355
Overview by Product Type.....	242	Overview by Product Type.....	299	Alpha Tau Medical Ltd. (Israel).....	355
7.5.3.2 French Radiopharmaceuticals Market		8.5.1.2 Japanese Radiopharmaceuticals Market		Eczacibasi-Monrol (Turkey).....	356
Overview by Application.....	244	Overview by Application.....	301	NTP Radioisotopes SOC Ltd. (South Africa).....	358
<b>7.5.4 Italy.....</b>	<b>246</b>	<b>8.5.2 China.....</b>	<b>303</b>	9.5 Country-wise Analysis of Rest of World	
7.5.4.1 Italian Radiopharmaceuticals Market		8.5.2.1 Chinese Radiopharmaceuticals Market		Radiopharmaceuticals Market.....	359
Overview by Product Type.....	247	Overview by Product Type.....	304	<b>9.5.1 Mexico.....</b>	<b>359</b>
7.5.4.2 Italian Radiopharmaceuticals Market		8.5.2.2 Chinese Radiopharmaceuticals Market		9.5.1.1 Mexican Radiopharmaceuticals Market	
Overview by Application.....	249	Overview by Application.....	306	Overview by Product Type.....	360
<b>7.5.5 Sweden.....</b>	<b>251</b>	<b>8.5.3 India.....</b>	<b>308</b>	9.5.1.2 Mexican Radiopharmaceuticals Market	
7.5.5.1 Swedish Radiopharmaceuticals Market		8.5.3.1 Indian Radiopharmaceuticals Market		Overview by Application.....	362
Overview by Product Type.....	252	Overview by Product Type.....	309	<b>9.5.2 Brazil.....</b>	<b>364</b>
7.5.5.2 Swedish Radiopharmaceuticals Market		8.5.3.2 Indian Radiopharmaceuticals Market		9.5.2.1 Brazilian Radiopharmaceuticals Market	
Overview by Application.....	254	Overview by Application.....	311	Overview by Product Type.....	365
<b>7.5.6 Rest of Europe.....</b>	<b>256</b>	<b>8.5.4 Australia.....</b>	<b>313</b>	9.5.2.2 Brazilian Radiopharmaceuticals Market	
7.5.6.1 Rest of Europe Radiopharmaceuticals Market		8.5.4.1 Australian Radiopharmaceuticals Market		Overview by Application.....	367
Overview by Product Type.....	257	Overview by Product Type.....	314	<b>9.5.3 Other Rest of World.....</b>	<b>369</b>
7.5.6.2 Rest of Europe Radiopharmaceuticals Market		8.5.4.2 Australian Radiopharmaceuticals Market		9.5.3.1 Other ROW Countries Radiopharmaceuticals	
Overview by Application.....	259	Overview by Application.....	316	Market Overview by Product Type.....	370
<b>8. ASIA-PACIFIC.....</b>	<b>261</b>	<b>8.5.5 South Korea.....</b>	<b>318</b>	9.5.3.2 Other ROW Countries Radiopharmaceuticals	
8.1 Asia-Pacific Radiopharmaceuticals Market		8.5.5.1 South Korean Radiopharmaceuticals Market		Market Overview by Application.....	372
Overview by Geographic Region.....	262	Overview by Product Type.....	319	<b>PART C: GUIDE TO THE INDUSTRY.....</b>	<b>374</b>
8.2 Asia-Pacific Radiopharmaceuticals Market		8.5.5.2 South Korean Radiopharmaceuticals Market		1. NORTH AMERICA.....	374
Overview by Product Type.....	264	Overview by Application.....	321	2. EUROPE.....	376
8.2.1 Radiopharmaceuticals Product Type Market		<b>8.5.6 Rest of Asia-Pacific.....</b>	<b>323</b>	3. ASIA-PACIFIC.....	377
Overview by Asia-Pacific Region.....	266	8.5.6.1 Rest of Asia-Pacific Radiopharmaceuticals		4. REST OF WORLD.....	378
8.2.1.1 SPECT Radioisotopes.....	266	Market Overview by Product Type.....	324	<b>PART D: ANNEXURE.....</b>	<b>379</b>
8.2.1.2 PET Radioisotopes.....	268	8.5.6.2 Rest of Asia-Pacific Radiopharmaceuticals		1. RESEARCH METHODOLOGY.....	379
8.2.1.3 Beta Emitters.....	270	Market Overview by Application.....	326	2. FEEDBACK.....	381
8.2.1.4 Alpha Emitters.....	272				
8.2.1.5 Other Radiopharmaceuticals.....	274				

## About Industry Experts

Industry Experts' market research, backed by years of experience and an analytical team dedicated to providing the most optimal business solutions, has been specifically designed to provide a variety of benefits, both current and future. Our leading-edge publications make the life easy for corporate strategists, investors, analysts and researchers, startups, consultants, financial and banking executives, academicians and many more. The company also provides customized research reports to cater the needs of the industry.

Business intelligence provides the critical link between comprehending prevailing market conditions and devising strategies to maximize parameters, such as revenues, profits and return on investment in order to gain market share. The significance of market research can be largely understood through the range of factors that impact businesses. These can comprise market size (current and projected), geographic market reach and demand and supply scenario, to name a few. Our ongoing quest to collect up to date and accurate information by conducting online surveys, personal interviews, taking the opinions of senior level executives will enable us to serve our clients better in every possible aspect.

[More about Industry Experts](#)



**Industry Experts, Inc.**  
14726 Ramona Ave, Suite S2  
Chino, CA 91710  
Greater Los Angeles  
United States  
Phone: +1-320-iXPERTS (497-3787)  
  
Email: [info@industry-experts.com](mailto:info@industry-experts.com)

**India Office**  
1-7-19/C, Street No. 8, Habsiguda  
Hyderabad – 500007  
India  
Phone: +91-40-4018-1314  
Fax: +91-40-2715-7746  
  
Website: <http://industry-experts.com>